Simvastatin

Limits on what this shows

• Key negative / null findings: In the same LIFESTAT cohort, maximal reactive-oxygen-species production was "similar among groups" (see the separate Oxidative Stress entry below, which counts this data point independently rather than repeating this one). Complex I+II-linked maximal coupled respiratory capacity, arguably the more clinically relevant overall measure, was not reduced. A separate simvastatin-specific human trial (Traustadóttir et al., 2008, described fully in the Oxygen delivery/utilization entry below) found no impairment of skeletal muscle function or exercise performance at a high simvastatin dose, which is hard to reconcile with a severe, generalized mitochondrial burden.
• At-risk subgroups: The LIFESTAT cohort was all on simvastatin 40 mg by report elsewhere in the same study series (dose not independently re-confirmed in the abstract text retrieved here); whether the complex II-linked deficit scales with dose above or below 40 mg was not tested. No pediatric, pregnancy, or renal-impairment data specific to this endpoint were located.

Regulatory status

Not listed as a monitoring parameter or interaction in the FDA label; mitochondrial respirometry is not a labeled or clinically standard test for statin therapy.

Population evidence

Dohlmann/Larsen et al. (LIFESTAT study), J Clin Endocrinol Metab, 2019, cross-sectional, 84 participants: 64 simvastatin users (25 myalgic, 39 asymptomatic, dose not stated in the abstract obtained) plus 20 untreated hypercholesterolemic controls. Complex II-linked respiration was reduced in both the myalgic and the asymptomatic statin groups relative to untreated controls. Maximally coupled complex I+II-linked respiratory capacity, the broader measure of overall mitochondrial function, "remained intact." When respiration was normalized to citrate synthase activity (a marker of mitochondrial content), rates were higher in the myalgic group than in the non-symptomatic or control groups, the opposite of what a simple loss-of-function story would predict. This is the same paper already cited for the muscle-CoQ10-null finding in the Orange CoQ10 entry above; here a different measured parameter from that paper is being counted (see Overlap map below).

Mechanism

Not established by this paper; the authors explicitly conclude the myalgia they observed was "not explained by reduced muscle CoQ10 or generalized mitochondrial dysfunction," so this is reported here as a real, tissue-confirmed but mechanistically unexplained respiratory-chain finding, not a named causal pathway. Tier B in vitro and animal work offers candidate, non-CoQ10 mechanisms that are mechanistically plausible extensions, not confirmed in this human cohort: Sanvee et al., 2021 (Biochem Pharmacol, C2C12 mouse myotubes and mouse skeletal muscle in vivo) reported simvastatin-induced mitochondrial superoxide accumulation together with mTORC2 inhibition, partly preventable with the mitochondria-targeted antioxidant MitoTEMPO, and tied this to impaired Rap1 geranylgeranylation, a mevalonate-pathway branch distinct from the CoQ10/farnesyl-pyrophosphate branch. Bonifacio et al., 2016 (Arch Toxicol, H9c2 cardiomyocytes and mice in vivo) reported simvastatin-induced mitochondrial dysfunction alongside increased atrogin-1 (a muscle-atrophy ubiquitin ligase) expression. Kwak et al., 2012 (Free Radic Biol Med, primary human skeletal myotubes in vitro) reported that simvastatin impairs ADP-stimulated respiration and increases mitochondrial oxidative stress in cultured human muscle cells; full quantitative detail beyond the title and abstract summary could not be independently retrieved after repeated access blocks, so it is cited here for its qualitative direction only.

Counter-evidence held on record

The same study found overall coupled mitochondrial capacity intact and, when normalized for mitochondrial content, respiration was not lower (and was numerically higher in the myalgic subgroup) rather than uniformly reduced. A separate simvastatin-specific exercise-physiology trial found no measurable impairment of aerobic or muscle function. This is a single cross-sectional cohort; it has not been independently replicated, and confounding by indication (statin users differ from non-users in cardiovascular risk factors, activity level, and possibly baseline muscle mitochondrial density) was not excluded by the study design. Framing caution: this is a laboratory tissue-respirometry finding in a single cohort, not a demonstrated clinical outcome, and it is not evidence of a validated "mitochondrial damage" syndrome from simvastatin. It should not be merged with, or read as independent confirmation of, the CoQ10 entry above; the two findings come from measuring different things in the same patients. No supplement or intervention is implied or recommended by this entry.

Limits on what this shows

• Key negative / null findings: LIFESTAT (Tier A, human, simvastatin-specific): muscle ROS production not different from controls. The Rasmussen RCT (Tier A, human, simvastatin-specific) was designed around a hypothesized reduction, not an increase, in oxidative stress, meaning the strongest available human evidence base for this drug does not support the "statins cause oxidative stress" framing as commonly stated, even though its own quantitative conclusion could not be independently confirmed here.
• At-risk subgroups: None identified from simvastatin-specific human data; any concern is currently limited to the in vitro/animal literature at the mitochondrial-compartment level.

Regulatory status

Not a labeled parameter; oxidative stress markers are not part of routine simvastatin monitoring.

Population evidence

Rasmussen et al., 2016, Redox Biology, "Simvastatin and oxidative stress in humans": a randomized, double-blinded, placebo-controlled clinical trial, simvastatin 40 mg for 14 days, designed on the stated hypothesis that "simvastatin may reduce oxidative stress." Repeated attempts to retrieve the paper's actual reported outcome data (beyond its stated hypothesis) were blocked by the source's access controls; the specific result is not asserted here and this citation is limited to confirming the trial's existence, design, and drug-specific, Tier A status (see Sources for the access-block flag). Separately, in the LIFESTAT cohort (already detailed in the Mitochondrial Burden entry above), maximal ROS production in skeletal muscle was "similar among" simvastatin-myalgic, simvastatin-asymptomatic, and untreated-control groups, a direct, verified, Tier A, tissue-level null result for simvastatin-induced oxidative stress.

Mechanism

Present at Tier B only, and compartment-specific: Kwak et al., 2012 (Free Radic Biol Med), simvastatin exposure in primary human skeletal myotubes in vitro, reported increased mitochondrial oxidative stress alongside impaired ADP-stimulated respiration. Sanvee et al., 2021 (Biochem Pharmacol), mouse C2C12 myotubes and mouse skeletal muscle, reported simvastatin-induced mitochondrial superoxide accumulation, partly reversible with a mitochondria-targeted antioxidant. Both are cell-culture/animal findings at supraphysiologic or locally concentrated drug exposure, not confirmed as a systemic or whole-tissue effect in simvastatin-treated humans.

Counter-evidence held on record

The only Tier A tissue-level test of oxidative stress in simvastatin-treated humans found no increase in muscle ROS production. A second Tier A human RCT was explicitly designed to test whether simvastatin reduces, not increases, oxidative stress; whether it succeeded could not be independently verified from the sources reachable here, and that gap is stated rather than resolved by assumption. Framing caution: do not present "statins increase oxidative stress" as an established simvastatin-specific finding in humans; the human muscle-tissue evidence located here runs the other way. The Tier B cell-culture signal is real and worth tracking, but it describes cultured cells under direct drug exposure, not a demonstrated in-body effect. This entry is distinct from, and should not be merged with, the Mitochondrial Burden entry above, which addresses respiration capacity rather than ROS production.

Limits on what this shows

• Key negative / null findings: Farrokhi et al. is the null finding itself: a placebo-controlled, crossover, simvastatin-specific trial found no beneficial or adverse effect on trace element status.
• At-risk subgroups: None identified from simvastatin-specific data. Confounding by indication is a live concern for any trace-element finding in dyslipidemic cohorts, since diet quality and inflammatory state both affect circulating copper and ceruloplasmin independent of statin use, and neither study cited here was designed to exclude this.

Regulatory status

Not a labeled parameter; copper status is not part of routine simvastatin monitoring.

Population evidence

Farrokhi et al., 2012, "Effects of statin therapy on serum trace element status in dyslipidemic patients: results of a randomized placebo-controlled cross-over trial": simvastatin 40 mg/day for four weeks "is not associated with any beneficial or adverse effects on trace element imbalances implicated in atherosclerosis pathogenesis" — a direct, simvastatin-specific, Tier A null result. Ghayour-Mobarhan et al., 2005, "Effect of statin therapy on serum trace element status in dyslipidaemic subjects": statin treatment reduced serum copper by approximately 9% and ceruloplasmin (the main copper-transport protein) by approximately 24%, alongside a roughly 9% reduction in serum zinc. Repeated attempts to confirm which specific statin(s) were used in this second study were blocked by the source's access controls; it is treated here as Tier C for simvastatin (unconfirmed cohort identity) rather than Tier A, per the mandatory cohort-identification rule.

Mechanism

No mechanism specific to simvastatin or to copper metabolism was identified or verified; a general, unconfirmed hypothesis in the trace-element literature links statin-associated changes in lipoprotein-bound transport proteins (ceruloplasmin is itself an acute-phase, copper-carrying plasma protein) to apparent shifts in circulating trace-element levels, parallel to the lipoprotein-carrier artifact already documented for vitamin E in this dossier's original vitamin E entry. This is noted as a plausible confound, not a confirmed mechanism.

Counter-evidence held on record

The only simvastatin-confirmed trial found no effect on trace elements at all, directly contradicting the reduction reported in the drug-unconfirmed study. Ceruloplasmin is an acute-phase reactant; any reduction associated with statin therapy could reflect reduced systemic inflammation (a plausible benefit of statin therapy generally) rather than a true copper-depletion effect, and neither source distinguishes these explanations. Framing caution: this is not established as a simvastatin effect. It is graded Yellow rather than Ungraded only because a real, numeric reduction was reported in the trace-element literature broadly; readers should not infer that simvastatin depletes copper on the strength of a study that could not be confirmed to include simvastatin at all.

Limits on what this shows

• Why no grade: A single simvastatin-specific study was located (Li et al., 2010, "How does short-term low-dose simvastatin influence serum prohepcidin levels in patients with end-stage renal disease? A pilot study," measuring prohepcidin, IL-6, CRP, ferritin, hemoglobin, albumin, and total cholesterol), but it is in a hemodialysis/end-stage renal disease population, where iron handling, hepcidin regulation, and inflammatory markers are dominated by the underlying renal disease and dialysis itself, not by simvastatin; confounding by indication cannot be excluded and is presumed to dominate in this population per this dossier's hard rules. Repeated attempts to retrieve this paper's actual numeric results were blocked by the source's access controls, so no direction or magnitude of effect can be responsibly stated from it. No general-population, non-dialysis, simvastatin-specific study of iron status, serum iron, ferritin, or hemoglobin was located. The trace-element panels cited in the Copper entry above (Farrokhi et al.; Ghayour-Mobarhan et al.) measured zinc, copper, and ceruloplasmin; iron was not reported as part of either panel in the material retrieved, so those sources are not extended to iron by inference.
• What would fill it: A simvastatin-specific human study, in a general dyslipidemic population rather than a renal-failure population, directly measuring serum iron, ferritin, transferrin saturation, or hemoglobin against placebo or untreated controls, with confounding by indication addressed by design (matched baseline cardiometabolic risk, diet, or a placebo-controlled design as in the copper/zinc trace-element trials above).

Limits on what this shows

• Key negative / null findings: The largest, most rigorously validated cohort located (Vieira-Silva, three cohorts, thousands of participants) found statin use associated with a lower prevalence of dysbiosis, the opposite of a "gut microbiome risk" claim. The diabetes-risk association in the FINRISK cohort was built on a very small explained-variance effect size (R² 0.02%) despite statistical significance, and diabetes itself is a clinical outcome, not a measured nutrient or direct microbiome-harm endpoint (per this dossier's hard rule against filing clinical outcomes as deficiency findings); it is reported here as a microbiome-composition finding, not as evidence that simvastatin causes diabetes.
• At-risk subgroups: None identified as simvastatin-specific. Confounding by indication is presumed and not excluded in any of these cohorts: statin users are systematically different from non-users in diet, body weight, physical activity, and cardiometabolic risk, all of which independently shape gut microbiome composition.

Regulatory status

Not a labeled parameter; gut microbiome status is not part of routine simvastatin monitoring or FDA labeling.

Population evidence

Vieira-Silva et al., 2020, Nature, "Statin therapy is associated with lower prevalence of gut microbiota dysbiosis": MetaCardis cohort (n=888) with two validation cohorts (n=282 cardiovascular-disease cohort; n=2,345 Flemish Gut Flora Project population cohort). Among obese participants, the dysbiotic Bact2 enterotype was present in 17.73% of those not on a statin versus 5.88% of those on a statin, a large, protective (not harmful) association, replicated across both validation cohorts; the specific statin(s) taken by participants were not identified in the material retrieved. Koponen et al., 2023/2024, Arterioscler Thromb Vasc Biol, FINRISK 2002 cohort, n=5,755, cross-sectional with 17+ years of register-based follow-up: statin use was associated with altered microbial composition, a small effect size (R² 0.02%, q=0.02) but statistically significant, with 13 differentially abundant species in fully adjusted models; 25 microbial features were associated with incident type 2 diabetes among statin users, including Bacteroides vulgatus (HR 1.286, q=0.03). The statin(s) used by participants were not specified in the material retrieved.

Mechanism

Plausible but not simvastatin-confirmed: She et al., 2024, Cell Metabolism, reported that statins aggravate insulin resistance through reduced blood GLP-1 levels "in a microbiota-dependent manner," proposing a mechanistic link between statin-associated microbiome shifts and a downstream metabolic outcome; the statin(s) studied were not confirmed in the material retrieved. Han et al., 2023, Nature Microbiology, reported that microbiota-derived tryptophan catabolites mediate a chemopreventive effect of statins on colorectal cancer, again describing statins as associated with reduced, not increased, dysbiosis; statin identity not confirmed.

Counter-evidence held on record

The single largest and most replicated finding located (Vieira-Silva, validated in three independent cohorts) runs opposite to a "risk" framing: statin use tracked with less, not more, microbiome dysbiosis. No cohort confirmed simvastatin as the statin used, so none of this evidence can be attributed to simvastatin specifically rather than to statins as a class or to confounding by the underlying cardiometabolic indication. Framing caution: "gut microbiome risk" is not established as a simvastatin-specific finding, and the strongest large-cohort evidence located actually points toward a protective association for statins as a class. This entry should not be read as confirming a consumer claim that statins damage gut bacteria; it documents that a real, unresolved, class-level and direction-mixed literature exists, with confounding by indication not excluded in any source cited.

Limits on what this shows

• Key negative / null findings: Traustadóttir et al. is itself the key null finding: direct measurement of oxygen kinetics and aerobic capacity in simvastatin users at the highest labeled dose showed no impairment.
• At-risk subgroups: None identified from simvastatin-specific data. The sample size (n=10) is small, so this null result bounds but does not close the question; a larger or longer trial could still detect a smaller effect.

Regulatory status

Not a labeled parameter; cardiorespiratory fitness testing is not part of routine simvastatin monitoring.

Population evidence

Traustadóttir et al., 2008, "High-dose statin use does not impair aerobic capacity or skeletal muscle function in older adults": randomized intervention study, n=10 (9 men, 1 woman), ages 55–76, elevated LDL-cholesterol at baseline (mean 4.2 ± 0.2 mmol/L), simvastatin 80 mg/day for 12 weeks (the FDA-restricted high dose). LDL and total cholesterol fell significantly (P <.01); HDL and triglycerides were unchanged. "No significant changes were observed in aerobic capacity, endurance, [or] oxygen kinetics," and no measurable change occurred in maximal strength, muscular power, or muscular endurance; no subject reported myalgia, cramps, or weakness. This is a small, simvastatin-specific, Tier A trial at the highest labeled dose, and its result is a clean null.

Mechanism

The only mechanism identified is the one already graded in the CoQ10 entry above: coenzyme Q10 is a required electron carrier in the mitochondrial electron transport chain, the site where oxygen is consumed to regenerate ATP, so a reduction in CoQ10 is mechanistically capable of impairing oxygen utilization. This dossier does not grade that mechanism a second time here; it is cross-referenced, not re-counted (see Overlap map below). No mechanism independent of CoQ10 was identified for this category.

Counter-evidence held on record

The only simvastatin-specific human trial to directly measure this endpoint found no effect, at the highest labeled dose, over 12 weeks. This is a small trial (n=10) and has not been independently replicated at this dose and duration. Framing caution: this category is graded Yellow because the supporting mechanism is real but entirely derivative of the CoQ10 entry above, not because independent oxygen-utilization evidence points toward harm; the one direct simvastatin-specific measurement available argues against a clinically meaningful effect. Do not present this as a second, independent confirmation of the CoQ10 finding.

Limits on what this shows

• Key negative / null findings: None identified specific to ATP content; no study located tested for or reported an absence of ATP reduction under simvastatin exposure in a muscle-cell model. This absence of a null result is itself notable and is stated rather than treated as confirmation, since Tier B in vitro findings at supraphysiologic concentrations do not reliably predict a clinical human effect.
• At-risk subgroups: Cannot be assessed; no human dose-response or subgroup data exist for this specific endpoint.

Regulatory status

Not a labeled parameter; muscle ATP content is not part of routine simvastatin monitoring.

Population evidence

No Tier A human population evidence was located. The closest human tissue-level study (LIFESTAT, cited in the Mitochondrial Burden entry above) measured mitochondrial oxygen flux/respiration, a related but distinct parameter from cellular ATP content, and is not re-counted here as ATP-specific evidence.

Mechanism

Tier B, consistent across independent models: Masters et al., 1995, neonatal rat skeletal myocytes exposed to pravastatin, lovastatin, and simvastatin in vitro, reported that "protein synthesis and ATP levels were the most sensitive indicators of toxicity," with simvastatin among the statins tested. Wat et al., 2016, rat L6 skeletal myoblast cell line, reported that "simvastatin reduced the ATP production in L6 cells," an effect dose-dependently prevented by a co-administered herbal extract in that study (the extract itself is not relevant to this dossier and is not endorsed here). Sanvee et al., 2021, mouse C2C12 myoblasts and myotubes, reported that "simvastatin decreased the cellular ATP content in both myoblasts and myotubes," with myoblasts more sensitive than differentiated myotubes; a separate 2021 paper from the same group (cited in the Mitochondrial Burden entry) tied a related mitochondrial-superoxide/mTORC2 effect to impaired geranylgeranylation, a mevalonate-pathway branch distinct from CoQ10 synthesis. Kuretu et al., 2024, PLoS One, mouse C2C12 cells, examined simvastatin's effect on cellular ATP production alongside insulin-signaling and glucose-handling proteins. Separately, Vaughan et al., 2013, reported that ubiquinol (reduced CoQ10) rescues simvastatin-suppressed mitochondrial content, function, and metabolism in muscle cells; this finding is CoQ10-mediated and is cross-referenced to, not re-counted within, this entry (see Overlap map below).

Counter-evidence held on record

No contradicting Tier A or Tier B evidence was located; the absence found here is an absence of any human measurement at all, not a contradicting result. This should be read as an evidence gap on the human side of an otherwise consistent preclinical signal, not as a demonstrated human effect. Framing caution: "statins drain your cellular energy" is a common consumer-marketing phrase; the preclinical signal behind it is real and reasonably consistent, but it has not been shown directly in human muscle from simvastatin users, and none of the in vitro concentrations used in these studies were confirmed here to correspond to clinically achieved simvastatin exposure. No supplement or dose is recommended by this entry.